Previous close | 51.64 |
Open | 52.14 |
Bid | 48.06 x 800 |
Ask | 48.38 x 500 |
Day's range | 46.60 - 52.14 |
52-week range | 25.57 - 75.02 |
Volume | |
Avg. volume | 954,438 |
Market cap | 2.748B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.
Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...